Внимание ! Нужна регистрация!
Age-related macular degeneration (AMD) is the leading cause of blindness in older persons in the United States. By 2050, the prevalence of early AMD is expected to double, affecting 17.8 million Americans. The disease can be divided into 2 forms: dry (nonexudative or nonneovascular) and wet (exudative or neovascular). Nonneovascular AMD is characterized by the presence of drusen, retinal pigment epithelial (RPE) changes, and atrophy of the central macula. In neovascular AMD, rapid deterioration of vision occurs due to accumulation of subretinal fluid, intraretinal fluid (Figures 1 and 2), RPE detachments, hemorrhage, and exudates and the formation of fibrotic scarring. Presently, beyond supplemental vitamins, there are no therapeutic options for the treatment of nonneovascular AMD. However, multiple options exist for patients with neovascular AMD. This article will focus on current, novel, and emerging therapies for neovascular AMD.